Lyell Immunopharma (NASDAQ:LYEL) Announces Quarterly Earnings Results

Lyell Immunopharma (NASDAQ:LYEL) released its quarterly earnings data on Wednesday. The company reported ($1.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.78) by $1.68, FiscalAI reports. The firm had revenue of $0.00 million for the quarter, compared to analyst estimates of $0.00 million. Lyell Immunopharma had a negative return on equity of 84.36% and a negative net margin of 794,858.12%.

Lyell Immunopharma Price Performance

NASDAQ:LYEL traded down $0.18 during trading hours on Friday, reaching $19.89. 29,105 shares of the company were exchanged, compared to its average volume of 95,294. The company has a market capitalization of $463.92 million, a P/E ratio of -1.44 and a beta of -0.05. Lyell Immunopharma has a 1-year low of $7.65 and a 1-year high of $45.00. The business has a 50 day moving average of $22.19 and a 200 day moving average of $23.52.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on LYEL shares. Wall Street Zen lowered Lyell Immunopharma from a “hold” rating to a “sell” rating in a research note on Saturday, May 2nd. Zacks Research lowered Lyell Immunopharma from a “hold” rating to a “strong sell” rating in a research note on Tuesday, April 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Lyell Immunopharma in a research note on Tuesday, April 21st. Robert W. Baird set a $49.00 target price on Lyell Immunopharma and gave the stock an “outperform” rating in a research note on Thursday, April 30th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $44.00 target price on shares of Lyell Immunopharma in a research note on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $43.00.

Insider Buying and Selling

In related news, insider Gary K. Lee sold 1,671 shares of the stock in a transaction that occurred on Wednesday, February 11th. The stock was sold at an average price of $23.39, for a total transaction of $39,084.69. Following the sale, the insider owned 16,938 shares of the company’s stock, valued at $396,179.82. This represents a 8.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, COO Stephen J. Hill sold 1,236 shares of the stock in a transaction that occurred on Wednesday, February 11th. The stock was sold at an average price of $23.39, for a total value of $28,910.04. Following the sale, the chief operating officer directly owned 17,795 shares in the company, valued at $416,225.05. This represents a 6.49% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 11,310 shares of company stock valued at $264,285 over the last 90 days. 6.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Lyell Immunopharma

Large investors have recently added to or reduced their stakes in the stock. AQR Capital Management LLC grew its position in Lyell Immunopharma by 773.5% during the first quarter. AQR Capital Management LLC now owns 174,279 shares of the company’s stock worth $94,000 after buying an additional 154,327 shares in the last quarter. Marshall Wace LLP acquired a new stake in Lyell Immunopharma during the second quarter worth approximately $94,000. Bridgeway Capital Management LLC acquired a new stake in shares of Lyell Immunopharma in the 2nd quarter valued at $159,000. Walleye Capital LLC acquired a new stake in shares of Lyell Immunopharma in the 2nd quarter valued at $258,000. Finally, ExodusPoint Capital Management LP acquired a new stake in shares of Lyell Immunopharma in the 4th quarter valued at $262,000. Institutional investors and hedge funds own 66.05% of the company’s stock.

About Lyell Immunopharma

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.